Literature DB >> 9111992

Mutation of RET codon 768 is associated with the FMTC phenotype.

L M Boccia1, J S Green, C Joyce, C Eng, S A Taylor, L M Mulligan.   

Abstract

Multiple endocrine neoplasia type 2A (MEN 2A), type 2B (MEN 2B), and familial medullary thyroid carcinoma (FMTC) are inherited cancer syndromes resulting from mutations in the RET proto-oncogene. Missense mutations of five codons in exons 10 and 11 are found in both MEN 2A and FMTC families, while mutations at codon 768 in exon 13 have been identified in three FMTC families. We report here the results of mutation analysis on a large multi-generation family with multiple cases of medullary thyroid carcinoma (MTC) or C-cell hyperplasia and two individuals with isolated adrenal medullary hyperplasia. A mutation in exon 13, which alters codon 768 from a GAG (Glu) to a GAC (Asp), was found to segregate with the FMTC phenotype in this family but not with the adrenal medullary hyperplasia. These findings suggest that the codon 768 mutation does not predispose to adrenal medullary hyperplasia, but is an accurate predictor of the MTC phenotype in this family.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9111992     DOI: 10.1111/j.1399-0004.1997.tb02424.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  12 in total

1.  The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial.

Authors:  J Oriola; I Halperin; F Rivera-Fillat; H Donis-Keller
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

2.  Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.

Authors:  Syed A Ahmed; Karen Snow-Bailey; W Edward Highsmith; Weimin Sun; Raymond G Fenwick; Rong Mao
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

3.  Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg.

Authors:  S Dvorakova; E Vaclavikova; J Duskova; P Vlcek; A Ryska; B Bendlova
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

Review 4.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

5.  The RET mutation E768D confers a late-onset familial medullary thyroid carcinoma -- only phenotype with incomplete penetrance: implications for screening and management of carrier status.

Authors:  Tabib Dabir; Steven J Hunter; Colin F J Russell; Damien McCall; Patrick J Morrison
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

Review 6.  Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Authors:  Samuel A Wells; Furio Pacini; Bruce G Robinson; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2013-06-06       Impact factor: 5.958

7.  Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma.

Authors:  F Lesueur; M Corbex; J D McKay; J Lima; P Soares; P Griseri; J Burgess; I Ceccherini; S Landolfi; M Papotti; A Amorim; D E Goldgar; G Romeo
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

Review 8.  Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.

Authors:  J R Hansford; L M Mulligan
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

9.  Genotype-phenotype correlations in Hungarian patients with hereditary medullary thyroid cancer.

Authors:  Attila Patocs; Izabella Klein; Aniko Szilvasi; Peter Gergics; Miklos Toth; Zsuzsa Valkusz; Erzsebet Forizs; Peter Igaz; Yousuf Al-Farhat; Attila Tordai; Andras Varadi; Karoly Racz; Olga Esik
Journal:  Wien Klin Wochenschr       Date:  2006-07       Impact factor: 1.704

10.  Linkage disequilibrium mapping in the Newfoundland population: a re-evaluation of the refinement of the Bardet-Biedl syndrome 1 critical interval.

Authors:  Yanli Fan; Jane S Green; Alison J Ross; Philip L Beales; Patrick S Parfrey; William S Davidson
Journal:  Hum Genet       Date:  2004-10-23       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.